A
Arlene E. Kohn
Researcher at Indiana University
Publications - 10
Citations - 2790
Arlene E. Kohn is an academic researcher from Indiana University. The author has contributed to research in topics: Risperidone & Autism. The author has an hindex of 9, co-authored 10 publications receiving 2631 citations. Previous affiliations of Arlene E. Kohn include Riley Hospital for Children & Indiana University – Purdue University Indianapolis.
Papers
More filters
Journal ArticleDOI
Risperidone in Children with Autism and Serious Behavioral Problems
James T. McCracken,James J. McGough,Bhavik Shah,Pegeen Cronin,Daniel Hong,Michael G. Aman,L. Eugene Arnold,Ronald L. Lindsay,Patricia L. Nash,Jill A. Hollway,Christopher J. McDougle,David J. Posey,Naomi B. Swiezy,Arlene E. Kohn,Lawrence Scahill,Andrés Martin,Kathleen Koenig,Fred R. Volkmar,Deirdre H. Carroll,Allison Lancor,Allison Lancor,Elaine Tierney,Jaswinder K. Ghuman,N. González,Marco A. Grados,Benedetto Vitiello,Louise Ritz,Mark Davies,James Robinson,Donald J. McMahon +29 more
TL;DR: Risperidone was effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior in children with autistic disorder and the benefit was maintained at six months.
Journal ArticleDOI
Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity
David J. Posey,David J. Posey,Michael G. Aman,L. Eugene Arnold,Yaser Ramadan,Andrea N. Witwer,Ronald L. Lindsay,Christopher J. McDougle,Naomi B. Swiezy,Arlene E. Kohn,James T. McCracken,Bhavik Shah,Pegeen Cronin,James J. McGough,Lisa Sea Yun Lee,Lawrence Scahill,Andrés Martin,Kathleen Koenig,Deirdre H. Carroll,Christopher Young,Allison Lancor,Elaine Tierney,Jaswinder K. Ghuman,N. González,Marco A. Grados,Benedetto Vitiello,Louise Ritz,Shirley Chuang,Mark Davies,James Robinson,Donald J. McMahon +30 more
TL;DR: Methylphenidate was often efficacious in treating hyperactivity associated with pervasive developmental disorders, but the magnitude of response was less than that seen in typically developing children with attention-deficit/hyperactivity disorder.
Journal ArticleDOI
Medication and Parent Training in Children with Pervasive Developmental Disorders and Serious Behavior Problems: Results from a Randomized Clinical Trial.
Michael G. Aman,Christopher J. McDougle,Lawrence Scahill,Benjamin L. Handen,L. Eugene Arnold,Cynthia R. Johnson,Kimberly A. Stigler,Karen Bearss,Eric Butter,Naomi B. Swiezy,Denis D. Sukhodolsky,Yaser Ramadan,Stacie L. Pozdol,Roumen Nikolov,Luc Lecavalier,Arlene E. Kohn,Kathleen Koenig,Jill A. Hollway,Patricia Korzekwa,Allison Gavaletz,James A. Mulick,Kristy L. Hall,James Dziura,Louise Ritz,Stacie Trollinger,Sunkyung Yu,Benedetto Vitiello,Ann Wagner +27 more
TL;DR: Medication plus PT resulted in greater reduction of serious maladaptive behavior than MED in children with PDDs, with a lower risperidone dose.
Risperidone Treatment of Autistic Disorder: Longer-Term Benefits and Blinded Discontinuation After 6 Months
Michael G. Aman,L. Eugene Arnold,Ronald L. Lindsay,Patricia L. Nash,Jill A. Hollway,James T. McCracken,Bhavik Shah,James J. McGough,Pegeen Cronin,Lisa Lee,Christopher J. McDougle,David J. Posey,Naomi B. Swiezy,Arlene E. Kohn,Lawrence Scahill,Andrés Martin,Kathleen Koenig,Fred R. Volkmar,Deirdre H. Carroll,Allison Lancor,Kennedy Krieger,Elaine Tierney,Jaswinder K. Ghuman,N. González,Marco A. Grados,Benedetto Vitiello,Louise Ritz,Mark Davies,Nathan Kline,James Robinson,Donald J. McMahon +30 more
TL;DR: Risperidone showed persistent efficacy and good tolerability for intermediate-length treatment of children with autism characterized by tantrums, aggression, and/or self-injurious behavior.
Journal ArticleDOI
Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials
L. Eugene Arnold,Benedetto Vitiello,Christopher J. McDougle,Lawrence Scahill,Bhavik Shah,N. González,Shirley Chuang,Mark Davies,Jill A. Hollway,Michael G. Aman,Pegeen Cronin,Kathleen Koenig,Arlene E. Kohn,Donald J. McMahon,Elaine Tierney +14 more
TL;DR: Risperidone was superior to placebo in reducing symptoms of most concern to parents of autistic children with irritable behavior, and individualized participant-chosen target symptoms seems a reliable, sensitive, efficient, and consumer-friendly way to assess treatment effect and might have clinical application.